<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232882</url>
  </required_header>
  <id_info>
    <org_study_id>D2452L00003</org_study_id>
    <nct_id>NCT00232882</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.</brief_title>
  <official_title>Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin receptor antagonists (ARA), beta-blockers and diuretics do not seem to confer&#xD;
      equivalent cardiovascular protection in hard outcomes clinical trials (beta blockers&#xD;
      inferior). These results may be explained by differences in their effects on sympathetic&#xD;
      activity, oxidative stress, inflammation and renin angiotensin system activation.&#xD;
&#xD;
      How diuretic addition to first line therapy with ARAs and beta-blockers modulates&#xD;
      neurohumoral and hemodynamic parameters is not well understood.&#xD;
&#xD;
      The main hypothesis of this study is that an ARA (candesartan) combined or not with a&#xD;
      diuretic will not increase sympathetic activity as much as a beta blocker (atenolol).&#xD;
      Secondary hypothesis are of similar nature but relate to hemodynamic parameters, oxidative&#xD;
      stress markers, inflammatory markers, or the renin angiotensin system.&#xD;
&#xD;
      The main objective of this study is to assess and compare the effects of candesartan and&#xD;
      atenolol and their combination with low dose diuretic therapy on the autonomic nervous&#xD;
      system, hemodynamic parameters,on oxidative stress, on inflammatory markers, and on the&#xD;
      renin-angiotensin system.&#xD;
&#xD;
      Protocol sponsored by Astra Zeneca canada&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION.&#xD;
&#xD;
      Three large clinical trials (STOP-2, HOPE, LIFE) {Hansson, Lindholm, et al. 1999}{Dahlof,&#xD;
      Devereux, et al. 2002}{Yusuf, Sleight, et al. 2000} have suggested that drugs that&#xD;
      specifically inhibit the renin angiotensin system (RAS) such as ACE inhibitors and&#xD;
      Angiotensin Receptor Antagonists (ARA) have blood pressure-independant cardiovascular&#xD;
      protecting effects. In the most recent of these studies, the LIFE trial, Losartan-based&#xD;
      therapy was superior to atenolol-based therapy in hypertensive patients with left ventricular&#xD;
      hypertrophy {Dahlof, Devereux, et al. 2002}. Very recently, the ALLHAT mega-trial suggested&#xD;
      that diuretics were as good as ACE inhibitors for cardiovascular protection in hypertensive&#xD;
      patients {Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized&#xD;
      to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent&#xD;
      Heart Attack Trial (ALLHAT-LLT)}. These apparently conflicting results underline that the&#xD;
      mechanisms of cardiovascular protections are not well understood.&#xD;
&#xD;
      ARAs {Balt, Mathy, et al. 2001}{Moreau, Richer, et al. 1993} have sympathoinhibitory&#xD;
      properties while beta-blockers induce a small counterregulatory activation of the sympathetic&#xD;
      system {Lijnen, Amery, et al. 1979}{Sundlof, Wallin, et al. 1983}{van den Meiracker, Man in&#xD;
      't Veld AJ, et al. 1988}.We have shown recently that telmisartan prevents the increase in NE&#xD;
      normally associated with a reduction in BP while there are reports that diuretics tend to&#xD;
      stimulate the sympathetic system {Fernandez, Snedden, et al. 1987}{Lake, Ziegler, et al.&#xD;
      1979}. It has been suggested that the superiority of ARAs could be due to their unique&#xD;
      effects on the autonomic nervous system.&#xD;
&#xD;
      Angiotensin II receptor antagonism also decrease the oxidative stress induced by angiotensin&#xD;
      II and aldosterone {de Cavanagh, Ferder, et al. 1999}{Hornig, Landmesser, et al.&#xD;
      2001}{Onozato, Tojo, et al. 2002}.We have also shown that telmisartan decreases plasma&#xD;
      aldosterone and should therefore decrease the oxidative stress associated with a reduction in&#xD;
      aldosterone Hydrochlorothiazide and beta-blockers have not been shown to have antioxidative&#xD;
      properties {Welch &amp; Wilcox 2001}{Taddei, Virdis, et al. 2001}. It is possible that oxidative&#xD;
      stress partly explains the differences between pharmacological agents.&#xD;
&#xD;
      Patients included in high blood pressure clinical trials are randomized to a therapeutic&#xD;
      strategy meaning that a stepped care approach is taken. Hypertensive patients frequently need&#xD;
      more than one drug for appropriate blood pressure control. Consequently, about half of study&#xD;
      patients in these trials end up taking more than one drug during the study. First step&#xD;
      therapy is by definition prescribed to all study subjects but second or third step therapy&#xD;
      are not as well defined. In the HOPE trial, ramipril was added on top of usual treatment.&#xD;
      Most of the patients included in HOPE, LIFE, STOP-2 and ALLHAT took at least one other&#xD;
      antihypertensive drug, most frequently a thiazide diuretic. Though results were reported as&#xD;
      being ACE inhibitor or ARA based, they mostly reflect a mix of single drug and multiple drugs&#xD;
      therapy. Whether the beneficial effects of ARAs and beta-blockers are modulated by thiazide&#xD;
      diuretics is presently unknown.&#xD;
&#xD;
      We designed a parallel study that primarily assesses the differences between ARAs, diuretics&#xD;
      and beta-blockers. The simultaneously measured parameters reflect renin-angiotensin system&#xD;
      activity, sympathetic activity, oxidative stress and systemic inflammation. Secondarily, this&#xD;
      study assesses the effects of ARA-diuretic and B-blocker-diuretic combinations on the same&#xD;
      parameters.&#xD;
&#xD;
      Results from this study will help to understand the results from the previously mentioned&#xD;
      clinical trials. The forced titration from monotherapy to a combination therapy will allow us&#xD;
      to measure the influence of drug addition on clinically significant parameters. The&#xD;
      simultaneous assessment of renin-angiotensin system activity , sympathetic activity,&#xD;
      oxidative stress and systemic inflammation will allow us to observe baseline and&#xD;
      pharmacologically-induced associations.&#xD;
&#xD;
      It is also probable that results from this study will have direct clinical influences on high&#xD;
      blood pressure therapeutic strategies. Physicians treating hypertension frequently have to&#xD;
      choose between increasing drug doses to their maximum or adding a new drug. It is presently&#xD;
      unknown if one strategy offers more benefits than the other. This study should provide&#xD;
      physicians with clues about the expected benefits for each approach.&#xD;
&#xD;
      GOALS&#xD;
&#xD;
      To assess and compare the effects of candesartan and atenolol combined with low dose diuretic&#xD;
      therapy on the autonomic nervous system, on oxidative stress, on inflammatory markers, and on&#xD;
      the renin-angiotensin system.&#xD;
&#xD;
      To assess and compare the effects of candesartan and atenolol and low dose diuretic therapy&#xD;
      on the autonomic nervous system, on inflammatory markers, on oxidative stress, on&#xD;
      inflammatory markers, and on the renin angiotensin system.&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      1. To measure and compare the effects candesartan 16 mg + HCT 12.5 mg, candesartan 16 mg +&#xD;
      HCT 25.0 mg, and atenolol 100 + 12.5 mg on noradrenalin release 4h post-dose, at trough, and&#xD;
      after a 10 minute stand.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        1. To measure and compare the effects candesartan 16 mg + HCT 12.5 mg, candesartan 16 mg +&#xD;
           HCT 25.0 mg, and atenolol 100 + 12.5 mg on :&#xD;
&#xD;
             1. frequency power spectral analysis 4h post-dose, and after a 10 minute stand.&#xD;
&#xD;
             2. oxidative stress, inflammatory markers and adhesion molecules 4h post-dose.&#xD;
&#xD;
             3. renin, aldosterone and angiotensin II release/production 4h post-dose and at&#xD;
                trough.&#xD;
&#xD;
             4. Insulin and glucose plasma concentration&#xD;
&#xD;
        2. To measure and compare the influences of HCT 25 mg, candesartan 16 mg, and atenolol 100&#xD;
           mg monotherapy on:&#xD;
&#xD;
             1. noradrenalin release 4h post-dose, at trough, and after a 10 minute stand.&#xD;
&#xD;
             2. frequency power spectral analysis 4h post-dose, and after a 10 minute stand.&#xD;
&#xD;
             3. oxidative stress, inflammatory markers and adhesion molecules 4h post-dose.&#xD;
&#xD;
             4. renin, aldosterone and angiotensin II release/production 4h post-dose and at&#xD;
                trough.&#xD;
&#xD;
             5. Insulin and glucose plasma concentration&#xD;
&#xD;
      DESIGN&#xD;
&#xD;
      Prospective, randomized, open label, 3 arm, 2 period parallel study preceded by a placebo run&#xD;
      in period in non-diabetic patients with essential hypertension.&#xD;
&#xD;
      Titration period: introduction of hydrochlorothiazide (12.5 mg daily), atenolol (50 mg&#xD;
      daily), and candesartan (8 mg daily) in the diuretic, beta-blocker and angiotensin receptor&#xD;
      blocker groups respectively. First study period (4 weeks), comparison of hydrochlorothiazide&#xD;
      25 mg, atenolol 100 mg, and candesartan 16mg. Second study period (4 weeks), comparison of&#xD;
      hydrochlorothiazide 25 mg + candesartan 16 mg, atenolol 100 mg + HCT 12.5 mg, and candesartan&#xD;
      16mg + HCT 12.5 mg. Measurement of study parameters at trough, 4h post-dose and after a 10&#xD;
      minutes stand after placebo and after each study period.&#xD;
&#xD;
      MEASURED STUDY PARAMETERS&#xD;
&#xD;
        1. Blood pressure&#xD;
&#xD;
        2. 24h blood pressure&#xD;
&#xD;
        3. Spectral analysis of heart rate (LF, HF, LF/HF)&#xD;
&#xD;
        4. Plasma&#xD;
&#xD;
             1. renin&#xD;
&#xD;
             2. aldosterone&#xD;
&#xD;
             3. angiotensin II&#xD;
&#xD;
             4. catecholamines&#xD;
&#xD;
             5. 8-epi-isoprostane&#xD;
&#xD;
             6. Thiobarbituric acid reactive substances (TBARS)&#xD;
&#xD;
             7. nitrotyrosine&#xD;
&#xD;
             8. interleukin 18&#xD;
&#xD;
             9. E selectine&#xD;
&#xD;
            10. C reactive protein&#xD;
&#xD;
            11. Insulin&#xD;
&#xD;
            12. glucose&#xD;
&#xD;
        5. Urine&#xD;
&#xD;
             1. 8-epi-isoprostane&#xD;
&#xD;
             2. sodium concentration&#xD;
&#xD;
             3. creatinine concentration&#xD;
&#xD;
      Protocol Sponsored by Astra Zeneca Canada&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma norepinephrine</measure>
    <time_frame>June 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Seated blood pressure</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. 24h ambulatory blood pressure</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Spectral analysis of heart rate (LF, HF, LF/HF)</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Plasma</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a. renin</measure>
    <time_frame>december 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>b. aldosterone</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c. angiotensin II</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>d. catecholamines</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>e. 8-epi-isoprostane</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>f. Thiobarbituric acid reactive substances (TBARS)</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>g. nitrotyrosine</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>h. interleukin 18</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>i. E selectine</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>j. C reactive protein</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>k. Insulin</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>l. glucose</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Urine</measure>
    <time_frame>June 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a. 8-epi-isoprostane</measure>
    <time_frame>December 2007</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Thiazide</intervention_name>
    <description>Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol Thiazide</intervention_name>
    <description>Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiazide Candesartan</intervention_name>
    <description>Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mild to moderate essential hypertension as defined by a morning mean DBP *90 mmHg and&#xD;
             * 109 mm Hg, a mean SBP * 200 mm H for two consecutive visits (Visits 2 and 3) during&#xD;
             the two-to-four week placebo run-in period,&#xD;
&#xD;
          2. Ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any woman not surgically sterile or menopausal who:&#xD;
&#xD;
               1. has a positive urine pregnancy test at screening (Visit 1) or baseline (Visit 3)&#xD;
&#xD;
               2. is breast feeding&#xD;
&#xD;
          2. Pre-menopausal women (last menstruation &lt; 1 year prior to start of run-in period) who:&#xD;
&#xD;
               1. are not surgically sterile; and/or&#xD;
&#xD;
               2. are of child-bearing potential and are NOT practicing acceptable means of birth&#xD;
                  control.&#xD;
&#xD;
          3. Known or suspected secondary hypertension.&#xD;
&#xD;
          4. Known reversible or non-reversible obstructive lung disease (e.g. asthma or COPD).&#xD;
&#xD;
          5. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:&#xD;
&#xD;
               1. ALT or AST greater than 2.0 times the upper limit of reference range;&#xD;
&#xD;
               2. Serum creatinine greater than 150 umol/L.&#xD;
&#xD;
          6. Uncorrected volume depletion.&#xD;
&#xD;
          7. NYHA functional class CHF III-IV (Refer to Appendices).&#xD;
&#xD;
          8. Coronary heart disease needing pharmacological therapy.&#xD;
&#xD;
          9. Stroke within the preceding six months.&#xD;
&#xD;
         10. PTCA within the preceding three months.&#xD;
&#xD;
         11. History of angioedema.&#xD;
&#xD;
         12. Clinically significant sinus bradycardia below 55 beats/min. at randomization.&#xD;
&#xD;
         13. Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant&#xD;
             cardiac arrhythmias as determined by the clinical Investigator.&#xD;
&#xD;
         14. Second or third degree AV block, left bundle branch block or any clinically relevant&#xD;
             conduction abnormality as determined by the clinical Investigator.&#xD;
&#xD;
         15. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant&#xD;
             stenosis of aortic or mitral valve.&#xD;
&#xD;
         16. Administration of digoxin.&#xD;
&#xD;
         17. Patients with a fasting glucose &gt; 7.0.&#xD;
&#xD;
         18. Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II&#xD;
             antagonists, *- blockers, *-blockers, calcium channel antagonists, direct vasodilators&#xD;
             that cannot be stopped for the trial.&#xD;
&#xD;
         19. Administration of other non-antihypertensive medications known to affect blood&#xD;
             pressure (e.g., oral corticosteroids, MAO inhibitors, nitrates) at any time during the&#xD;
             trial.&#xD;
&#xD;
         20. Chronic use of salt substitutes containing potassium chloride; potassium supplements;&#xD;
             extreme dietary restrictions.&#xD;
&#xD;
         21. Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.&#xD;
&#xD;
         22. Clinically significant hyperkalemia as defined by serum potassium level greater than&#xD;
             5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less&#xD;
             than 3.0 mEq/L.&#xD;
&#xD;
         23. Patients receiving any investigational therapy within one month of signing the&#xD;
             informed consent form.&#xD;
&#xD;
         24. Known hypersensitivity to any component of candesartan, atenolol or&#xD;
             hydrochlorothiazide.&#xD;
&#xD;
         25. Any other clinical condition which, in the opinion of the principal Investigator,&#xD;
             would not allow safe completion of the protocol and safe administration of trial&#xD;
             medication.&#xD;
&#xD;
         26. Known for allergy to sulfa or heparin&#xD;
&#xD;
         27. Blood donation in the preceding 2 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime Lamarre-Cliche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherches Cliniques de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recherches Cliniques de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>August 30, 2013</last_update_submitted>
  <last_update_submitted_qc>August 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <name_title>Maxime Lamarre-Cliche</name_title>
    <organization>Institut de Recherches Cliniques de Montreal</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Antihypertensive drugs</keyword>
  <keyword>Clinical Pharmacology</keyword>
  <keyword>Autonomic nervous system</keyword>
  <keyword>Renin angiotensin system</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Inflammatory markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

